This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Garcia, J. M. Articles by Marcelli, M. Search for Related Content PubMed PubMed Citation Articles by Garcia, J. M. Articles by Marcelli, M. Related Collections Metabolism

Active Ghrelin Levels and Active to Total Ghrelin Ratio in Cancer-Induced Cachexia

Department of Medicine, Division of Diabetes, Endocrinology, and Metabolism (J.M.G., M.G.-T., R.A.H., G.R.C., M.M.), Oncology (D.E.), and Cardiology (D.M.) and the Huffington Center on Aging (J.M.G., G.T., R.G.S.), Baylor College of Medicine, and Michael E. DeBakey Veterans Affairs Medical Center (J.M.G., M.G.-T., R.A.H., G.T., D.E., D.M., G.R.C., M.M.), Houston, Texas 77030

Address all correspondence and requests for reprints to: José M. Garcia, Michael E. DeBakey Veterans Affairs Medical Center, 2002 Holcombe Boulevard, Houston, Texas 77030. E-mail: jgarcia1{at}bcm.tmc.edu.

Anorexia and weight loss are negative prognostic factors in patients with cancer. Although total ghrelin levels are increased in energy-negative states, levels of the biologically active octanoylated ghrelin and the anorexigenic peptide YY (PYY) have not been reported in patients with cancer-induced cachexia. We hypothesized that abnormal ghrelin and/or PYY levels contribute to cancer-induced cachexia. We evaluated 21 patients with cancer-induced cachexia; 24 cancer patients without cachexia; and 23 age-, sex-, race-, and BMI-matched subjects without cancer. Active ghrelin levels and the active to total ghrelin ratio were significantly increased in subjects with cancer-induced cachexia, compared with cancer and noncancer controls. PYY levels were similar among groups. Appetite measured by a visual analog scale was not increased in subjects with cachexia. The increase in active ghrelin levels is likely to be a compensatory response to weight loss. Cachexia may be a state of ghrelin resistance because appetite does not correlate with ghrelin levels. Changes in the active to total ghrelin ratio suggest that a mechanism other than increased secretion must be responsible for the increase in active ghrelin levels. PYY is unlikely to play an important role in cancer-induced cachexia.

This article has been cited by other articles:

				S. Strassburg, S. D. Anker, T. R. Castaneda, L. Burget, D. Perez-Tilve, P. T. Pfluger, R. Nogueiras, H. Halem, J. Z. Dong, M. D. Culler, et al. Long-term effects of ghrelin and ghrelin receptor agonists on energy balance in rats Am J Physiol Endocrinol Metab, July 1, 2008; 295(1): E78 - E84. [Abstract] [Full Text] [PDF]

				J. M. Garcia, J. P. Cata, P. M. Dougherty, and R. G. Smith Ghrelin Prevents Cisplatin-Induced Mechanical Hyperalgesia and Cachexia Endocrinology, February 1, 2008; 149(2): 455 - 460. [Abstract] [Full Text] [PDF]

				M. D. DeBoer, X. Zhu, P. R. Levasseur, A. Inui, Z. Hu, G. Han, W. E. Mitch, J. E. Taylor, H. A. Halem, J. Z. Dong, et al. Ghrelin Treatment of Chronic Kidney Disease: Improvements in Lean Body Mass and Cytokine Profile Endocrinology, February 1, 2008; 149(2): 827 - 835. [Abstract] [Full Text] [PDF]

				M. Korbonits, D. Blaine, M. Elia, and J. Powell-Tuck Metabolic and hormonal changes during the refeeding period of prolonged fasting Eur. J. Endocrinol., August 1, 2007; 157(2): 157 - 166. [Abstract] [Full Text] [PDF]

				M. D. DeBoer, X. X. Zhu, P. Levasseur, M. M. Meguid, S. Suzuki, A. Inui, J. E. Taylor, H. A. Halem, J. Z. Dong, R. Datta, et al. Ghrelin Treatment Causes Increased Food Intake and Retention of Lean Body Mass in a Rat Model of Cancer Cachexia Endocrinology, June 1, 2007; 148(6): 3004 - 3012. [Abstract] [Full Text] [PDF]

				K. Lundholm, U. Korner, L. Gunnebo, P. Sixt-Ammilon, M. Fouladiun, P. Daneryd, and I. Bosaeus Insulin Treatment in Cancer Cachexia: Effects on Survival, Metabolism, and Physical Functioning Clin. Cancer Res., May 1, 2007; 13(9): 2699 - 2706. [Abstract] [Full Text] [PDF]

				J. M. Garcia and W. J. Polvino Effect on Body Weight and Safety of RC-1291, a Novel, Orally Available Ghrelin Mimetic and Growth Hormone Secretagogue: Results of a Phase I, Randomized, Placebo-Controlled, Multiple-Dose Study in Healthy Volunteers Oncologist, May 1, 2007; 12(5): 594 - 600. [Abstract] [Full Text] [PDF]

				Y. Sun, J. M. Garcia, and R. G. Smith Ghrelin and Growth Hormone Secretagogue Receptor Expression in Mice during Aging Endocrinology, March 1, 2007; 148(3): 1323 - 1329. [Abstract] [Full Text] [PDF]

				P. Costelli, M. Muscaritoli, M. Bossola, F. Penna, P. Reffo, A. Bonetto, S. Busquets, G. Bonelli, F. J. Lopez-Soriano, G. B. Doglietto, et al. IGF-1 is downregulated in experimental cancer cachexia Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2006; 291(3): R674 - R683. [Abstract] [Full Text] [PDF]

				S. Perboni and A. Inui Anorexia in cancer: role of feeding-regulatory peptides Phil Trans R Soc B, July 29, 2006; 361(1471): 1281 - 1289. [Abstract] [Full Text] [PDF]

				V. D. Dixit, A. T. Weeraratna, H. Yang, D. Bertak, A. Cooper-Jenkins, G. J. Riggins, C. G. Eberhart, and D. D. Taub Ghrelin and the Growth Hormone Secretagogue Receptor Constitute a Novel Autocrine Pathway in Astrocytoma Motility J. Biol. Chem., June 16, 2006; 281(24): 16681 - 16690. [Abstract] [Full Text] [PDF]

				M. J. Kleinz, J. J. Maguire, J. N. Skepper, and A. P. Davenport Functional and immunocytochemical evidence for a role of ghrelin and des-octanoyl ghrelin in the regulation of vascular tone in man Cardiovasc Res, January 1, 2006; 69(1): 227 - 235. [Abstract] [Full Text] [PDF]